Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial.

Objectives: Oral lichen plans (OLP) is a potentially malignant inflammatory mucocutaneous disease. CD133 is an investigated surface marker for cancer stem-like cells (CSCs) that may be involved in tumor initiation in head and neck carcinomas. We compared short-term clinical effectiveness of topical pimecrolimus as selective inflammatory cytokine release inhibitor with betamethasone cream for erosive/atrophic OLP and investigated the influence of this therapy on CD133 expression.

Injection of steroids intralesional in central giant cell granuloma cases (giant cell tumor): Is it free of systemic complications or not? A case report.

Central giant tumors commonly occur in long bones. In the oral and maxillofacial region, a counterpart coined with the term Central giant cell granuloma exists. Choung and Kaban classified central giant cell granulomas based on clinical and radiographic findings.

Efficacy of ImageJ in the assessment of apoptosis.

Objective: To verify the efficacy of ImageJ 1.43 n in determining the extent of apoptosis which is a complex and multistep process.

Study Design: Cisplatin in different concentrations was used to induce apoptosis in cultured Hep2 cells.

Maspin and MCM2 immunoprofiling in salivary gland carcinomas.

Background: The pathogenesis of salivary gland carcinomas is very complex and prognostic markers are difficult to find in these carcinomas of which the different subtypes have varying malignant potential. The study was conducted to examine the cellular distribution of maspin and MCM2 in salivary gland carcinomas and their value to predict lymph node metastasis.

Materials And Methods: Fifty three paraffin blocks of different lesions (15 muco-epidermoid carcinoma, 14 adenoid cystic carcinoma, 3 epi-myoepithelial carcinoma, 5 salivary duct carcinoma, 5 malignant pleomorphic adenoma, 6 polymorphous low grade adenocarcinoma and 5 acinic cell carcinoma) were prepared for immunohistochemical staining with maspin and MCM2 antibodies.